Stayble Therapeutics

Focus: Stayble Therapeutics is a Swedish biotech company focused on injectable treatments for back pain and musculoskeletal disorders. The company is in early clinical stages with a narrow therapeutic focus on discogenic pain and lumbar disc herniation.

Musculoskeletal

Profile data last refreshed 3h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Stayble Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Stayble Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Lactic Acid

Lumbar Disc Herniation

Phase 1

Clinical Trials (1)

NCT06022263STA363 in the Treatment of Lumbar Disc Herniation

Phase 1

Help build intelligence for Stayble Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-need musculoskeletal space where injectable solutions address significant unmet need in back pain management.
Public company status provides equity upside potential and access to capital markets for development funding.
Early-stage pipeline (Phase 1–2) offers hands-on involvement in translating mechanism to clinical proof-of-concept.

Watch Out For

Zero active job openings and undisclosed employee count signal minimal hiring and possible resource constraints for career growth.
Early clinical stage (no Phase 3 programs) means 5+ years to potential commercialization with execution risk and capital needs.
Lack of approved products, published data, and recent news limits visibility into company progress and scientific credibility.

Generated by Claude from Stayble Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

STA363

Low Back Pain

Phase 1

Clinical Trials (1)

NCT03055845A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain

Phase 1

STA363 containing 90 mg

Discogenic Pain

Phase 2

Clinical Trials (1)

NCT04673461Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo